OmniAb (OABI) Expected to Announce Earnings on Thursday

OmniAb (NASDAQ:OABI) is projected to announce its Q1 2025 earnings results after the market closes on Thursday, May 8th. Analysts expect OmniAb to post earnings of ($0.17) per share and revenue of $4.49 million for the quarter.

OmniAb (NASDAQ:OABI) last posted its earnings results on Tuesday, March 18th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $10.80 million for the quarter, compared to analyst estimates of $10.13 million. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. During the same period in the previous year, the firm posted ($0.14) EPS. On average, analysts expect OmniAb to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OmniAb Stock Performance

OABI stock opened at $1.68 on Tuesday. The company has a market capitalization of $205.19 million, a P/E ratio of -2.71 and a beta of 0.10. The company has a fifty day moving average price of $2.40 and a 200-day moving average price of $3.26. OmniAb has a 52-week low of $1.63 and a 52-week high of $4.96.

Analysts Set New Price Targets

A number of research firms have commented on OABI. Royal Bank of Canada reduced their price target on OmniAb from $7.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, March 27th. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of OmniAb in a report on Wednesday, March 19th. Finally, Benchmark reduced their price objective on shares of OmniAb from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th.

Insiders Place Their Bets

In other news, insider Charles S. Berkman sold 8,215 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total transaction of $30,231.20. Following the completion of the sale, the insider now owns 364,131 shares in the company, valued at $1,340,002.08. The trade was a 2.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kurt A. Gustafson sold 7,255 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total value of $26,625.85. Following the transaction, the chief financial officer now directly owns 206,211 shares in the company, valued at $756,794.37. The trade was a 3.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 67,985 shares of company stock worth $189,773. 8.60% of the stock is owned by corporate insiders.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.